Hyperprolactinaemia

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 8, Issue 2, 2008, Pages 216-219

  Demssie, Yared N ^a   Davis, Julian R E ^a,b  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BROMOCRIPTINE; CABERGOLINE; CIMETIDINE; CLOZAPINE; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN DERIVATIVE; HALOPERIDOL; METHYLDOPA; METOCLOPRAMIDE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; OPIATE DERIVATIVE; PERGOLIDE; PHENOTHIAZINE; PROLACTIN; QUETIAPINE; QUINAGOLIDE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VERAPAMIL;

BIOCHEMISTRY; CANCER SURGERY; CLINICAL EVALUATION; CONGENITAL MALFORMATION; CONTRACEPTION; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; HEART VALVE FIBROSIS; HUMAN; HYPERPROLACTINEMIA; LOADING DRUG DOSE; LOW DRUG DOSE; MOOD; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATHOPHYSIOLOGY; PREGNANCY; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; PROLACTINOMA; REMISSION; REVIEW; SIDE EFFECT; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT INDICATION; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; VALVULAR HEART DISEASE;

EID: 42549138016     PISSN: 14702118     EISSN: None     Source Type: Journal    
DOI: 10.7861/clinmedicine.8-2-216     Document Type: Review

References (21)

1. Casanueva FF, Molitch ME, Schlechte JA et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006;65:265-73.
2. Prabhakar VK, Davis JR. Hyperprolactinaemia. Best Pract Res Clin Obstet Gynaecol 2007; doi:10.1016/j.bpobgyn 2007.08.002.
3. Karavitaki N, Thanabalasingham G, Shore HC et al. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol (Oxf) 2006;65:524-9.
4. Davis JR. Prolactin and reproductive medicine. Review. Curr Opin Obstet Gynecol 2004;16:331-7.
5. Chong BW, Kucharczyk W, Singer W, George S. Pituitary gland MR: a comparative study of healthy volunteers and patients with microadenomas. Am J Neuroradiol 1994;15:675-9.
6. Molitch ME, Russell EJ. The pituitary 'incidentaloma'. Ann Intern Med 1990;112:925-31.
7. Vallette-Kasic S, Morange-Ramos I, Selim A et al. Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab 2002;87:581-8.
8. Webster J. Clinical management of prolactinomas. Baillieres Best Pract Res Clin Endocrinol Metab 1999;13:395-408.
9. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Review. Endocr Rev 2006;27:485-534.
10. Webster J, Piscitelli G, Polli A et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 1994;331:904-9.
11. Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992;13:220-40.
12. Losa M, Mortini P, Barzaghi R, Gioia L, Giovanelli M. Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J Clin Endocrinol Metab 2002;87:3180-6.
13. Molitch ME. Pituitary diseases in pregnancy. Semin Perinatol 1998;22:457-70.
14. Krupp P, Monka C. Bromocriptine in pregnancy: safety aspects. Klin Wochenschr 1987;65:823-7.
15. Colao A, Abs R, Bárcena DG et al. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol (Oxf) 2008;68:66-71.
16. Wieck A, Haddad PM. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review. Br J Psychiatry 2003;182:199-204.
17. Peter SA, Autz A, Jean-Simon ML. Bromocriptine-induced schizophrenia. J Natl Med Assoc 1993;85:700-1.
18. Colao A, DiSamo A, Cappabianca P et al. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 2003;349:2023-33.
19. Colao A, DiSamo A, Guerra E et al. Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol (Oxf) 2007;67:426-33.
20. Zanettini R, Antonini A, Gatto G et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356:39-46.
21. Sherlock M, Steeds R, Toogood AA. Dopamine agonist therapy and cardiac valve dysfunction. Clin Endocrinol (Oxf) 2007;67:643-4.